Analysis of T cell hybridomas. IV. Characterization of inducible suppressor cell hybridomas by unknown
ANALYSIS  OF  T  CELL  HYBRIDOMAS 
IV. Characterization  of Inducible Suppressor Cell Hybridomas* 
BY MUTSUHIKO  MINAMI, KENJI OKUDA, SHUICHI FURUSAWA, AND 
MARTIN E.  DORF 
From the Department  of Pathology, Harvard Medical School, Boston, Massachusetts  02115 
During the past several years, our laboratory has studied the mechanism of immune 
suppression in the 4-hydroxy-3-nitrophenyl acetyl (NP) 1 system. In this model system, 
both cell-mediated and humoral  immunity  (1-3)  have been analyzed.  The findings 
have  permitted  integration  of  the  data  into  a  single  linear  scheme  of  cellular 
interactions  (3-5).  Based on the  results obtained  in our and other laboratories that 
have investigated regulation by several types of suppressor T  cells, we proposed that 
at  least  three  distinct  T  cell  subsets were involved in  the phenomenon  of immune 
suppression  (3-5).  These T  cell subpopulations were termed Tsl, Ts~, and Ts~.  The 
major  criteria  that  are  used  to  distinguish  and  identify  the  various  cells  in  the 
suppressor cell pathway include:  (a) the binding specificity of the relevant cells, i.e., 
do the cells bind antigen or idiotype;  (b)  the surface phenotype of the cells;  (c)  the 
genetic  restrictions  at  either  the  H-2 or Igh gene complexes on  the  interactions  of 
either the cells or their soluble factors (TsF); and (d)  the kinetics of suppression, i.e., 
do the cells function in the induction or effector phase of the immune response? 
Tsx cells express the Ly-1+2  -  phenotype and possess NPb-related idiotypic receptors 
that bind antigen (1, 4). Tsx cells only function during the afferent or induction phase 
of the immune response (I), in contrast to the other forms of suppressor cells that can 
function during the effector or efferent phase of the immune response (4-6). Tsl cells 
and their factors (TsF1)  function by stimulating a  population of nonimmune T  cells 
to become Tsz cells that are idiotype- rather than antigen-specific (6,  7). It should be 
noted  that  these  conclusions  were  mainly  derived  from  experiments  that  used 
hybridoma-derived monoclonal TsF, to generate Tsz cells in the absence of antigen 
(7). Another important property of TsF~ is that it can induce Ts2 cells in any strain of 
mouse without  genetic  restrictions  (7).  Similar populations  of Ts~-like inducer cells 
have been described in several other suppressor cell systems (8-13). 
Ts2 cells differ radically from Tsl in their properties and function. In the NP system, 
Ts2  cells  are  antiidiotypic  and  can  be  shown  to  bind  idiotype-coated  plates  (6), 
although they do not bind the major NP b idiotypic determinants  (14). Ts2 cells bear 
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Lyt-2 and I-] determinants  (4,  15). These cells function  in the effector phase of the 
immune response, i.e., they are able to suppress contact sensitivity or plaque-forming 
cell responses in immune animals (6,  16). Another very important difference between 
Tsa and Ts2 cells concerns the genetic restrictions that govern their interactions with 
targets. Ts2 cells are restricted by genes in both the Igh and I-J complexes (4, 7). That 
is,  Ts2  cells  or  their  factors  will  not  function  unless  adoptively  transferred  into 
recipients that are homologous at both the H-2 (I-J) and Igh gene complexes (15). 
The efferent activity of Tsz cells led us to consider that these cells might be the final 
effectors of suppression.  However, this proved not  to be the case.  We observed that 
injection of Tsz ceils or TsF2 would not suppress an immune animal if the recipient 
mouse  had  been  treated  with  low  doses  of cycIophosphamide  (CY)  shortly  after 
antigen  immunization  (4).  This  suggested  that  a  highly  CY-sensitive cell  was  the 
target  of TsF2.  We  demonstrated  that  Ts3  cells  were  induced  as  a  consequence  of 
conventional  immunization  that  also  induced  the  T  cells  mediating  contact  or 
cutaneous sensitivity (CS)  (4). In addition, Ts3 cells were required for the modulation 
of NP-specific in vitro B cell responses (5). Antigen-activated Ts~ cells appeared to be 
inactive until appropriately triggered by Tsz cells or TsF2 (4, 5,  17). 
The Ts3 cells that  modulate  CS  responses  are antigen  specific and  H-2 and  Igh 
restricted  (4,  18). They express the Lyt-2  + phenotype and also carry I-J determinants 
(4). Ts3 cells produce an antigen-specific TsF3 that mediates suppression in the effector 
phase of the immune response (18).  The suppressive activity of Ts3 cells and TsF3 can 
be demonstrated in CY-treated recipients and, as is the case for TsFz, is restricted by 
I-J and  Igh  genes  (18).  Ts3 hybridomas  that  constitutively secrete TsF3  have been 
obtained in the NP system (18). 
Because the Ts3 hybridomas constitutively secreted TsF, analysis of the triggering 
process required for release of these biologically active mediators was not possible. An 
understanding of how mature Ts cells are triggered is particularly important for the 
Ts3 population since these cells may secrete the effector suppressor molecules. Ts3 cells 
are generated  by conventional  antigen  immunization  and consequently are present 
concomitant  with  helper or delayed type hypersensitivity effector T  cells  (4,  5,  17). 
The Ts3 population apparently expands and matures after immunization, but remains 
functionally  inactive  unless  triggered  by Ts2  cells  or  TsF2  (17,  19).  This  situation 
permits the primary immune response to proceed normally in the absence of suppres- 
sion. Once Ts~ cells or factors are generated, they will induce the terminal maturation 
of the Ts3 population  to secrete TsF3, which  in turn  rapidly modulates the immune 
response. Thus, both TsF~ and TsF3 function  in previously primed animals and can 
mediate suppression of either T  or B cell responses within  24 h  (4-6,  16). 
To  characterize  the  process  of Ts.~ activation,  we  generated  two  hybridoma cell 
lines  that  fail  to  release TsF~  unless  they are specifically activated  by TsF2.  These 
inducible TsF3-secreting hybridomas, termed pTs3, are the subject of this report. 
Materials and Methods 
Mice.  All mice were either purchased from The Jackson Laboratory, Bar Harbor, ME, or 
bred in the animal facilities at Harvard Medical School. Mice used were 3-12 mo old and were 
maintained on laboratory chow and acidified,  chlorinated water ad lib. They were maintained 
in accordance with the guidelines of the Committee on Animals of the Harvard Medical School 
and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute 
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Antigens.  NP-O-succinimide (NP-O-Su) was purchased from Biosearch Co., San Rafael, CA. 
Dimethylsulfoxide (DMSO)  was  purchased  from  Fisher Scientific Co.,  Pittsburgh,  PA.  2,4- 
dinitro-l-fluorobenzene (DNFB) and keyhole limpet hemocyanin (KLH) were obtained from 
Sigma Chemical Co., St. Louis, MO. 
Antisera.  Both  B10.A  (3R)  anti-B10.A  (5R)  (anti-I-J  k)  and  B10.A  (SR)  anti-B10.A  (3R) 
(anti-I-J  b)  were  produced  by immunization with spleen and lymph node cells, as described 
elsewhere (21).  Guinea pig anti-NP  b antiidiotype antisera were prepared as detailed elsewhere 
(22).  The characterization of these reagents was described previously (21). 
Preparation of Tsa Cells from Antigen Plates.  The methods for the preparation and enrichment 
of NP-binding T  cells were described in detail elsewhere (18).  In brief, 5 ×  107 regional lymph 
node or spleen cells from CKB  (H-2  k, Igh-1 b) and C57BL/6  (H-2  b, Igh-1 b) mice, which were 
immunized subcutaneously with 2 mg NP-O-Su or 100 #g NP-KLH i.p. in alum-pertussis (4), 
were added to purified anti-mouse immunoglobulin-coated petri dishes to remove B cells. The 
nonadherent T  cells were incubated on NP-bovine serum albumin-coated petri dishes for 45 
rain at room temperature. Nonadherent cells were removed by gentle swirling and the plates 
were placed on ice for 20 min. The antigen-binding  cells were collected from the plate by gentle 
pipetting and were used as the source of Tss cells. 
Hybridization  and  Screening of  Tsa  Hybridoma  Lines.  Ts3-enriched  CKB  or  C57BL/6  (B6) 
lymphocytes  were  hybridized  with  BW5147  T  lymphoma  cells.  The  polyethylene  glycol- 
mediated hybridizing method was exactly the same as previously reported (21). The hybridized 
Tss candidates were screened using a cytotoxicity test (18) with allele-specific anti-I-J and anti- 
NP  b antisera. Two fusions were performed: the CKB-pTs3-80 line was derived from a fusion of 
drug-marked BW5147 thymoma cells with NP-O-Su-primed lymph node cells, whereas the B6- 
pTs3-9 line was obtained from a fusion using antigen-adherent splenic T  cells from a NP-KLH- 
primed B6 mouse. The B6-pTs3-9 and CKB-pTs3-80 hybridoma lines were cloned by limiting 
dilution:  10 of the  11  clones tested  had the same phenotype and suppressive activity as the 
parental  line. All of the  hybridomas were cultured in RPMI  1640 containing 8%  fetal calf 
serum and 0.01  M  Hepes buffer. The two pTs3 hybridomas described in this report  (and two 
others not discussed) were unstable. Even though frozen aliquots were used to regenerate the 
lines, activity was lost  in a  few months. The hybridomas characterized  in this report are no 
longer available. 
In  Vitro Activation of pTsa Hybridoma with  TsF2.  B6-Ts2-28-, CKB-Ts2-59-, and  B6-Ts2-14- 
derived TsF2, which have been characterized and described elsewhere, were used for activation 
of pTss hybridomas in vitro. 5 ×  106 pTs3 hybridoma cells were cultured for 2 d in 10 ml RPMI 
1640 with 10% fetal calf serum and 0.1 mM Hepes plus 50 #1 TsF2 ascites fluid derived from B6 
or CKB Ts2 hybridomas or BW5147 tumor cells that were grown in (AKR ×  B6)F1 or (AKR 
×  CKB)F1 mice. After culture these activated pTss hybridomas were washed three times with 
Hanks' balanced salt solution (HBSS), resuspended in 10 ml RPMI  1640 with  10% fetal calf 
serum and 0.1 mM Hepes, and cultured for  1 d. The culture supernatant was then collected 
and tested for suppressive activity. 
In  Vitro Activation of NP-primed Lymph Node Ts3 Cells with TsF2.  Methods for the preparation 
and activation of NP-primed lymph node Ts3 cells were described in detail elsewhere (17).  In 
brief, 5 ×  108 regional lymph node cells from mice that were immunized subcutaneously with 
2 mg NP-O-Su were cultured with C3H.SW-Ts2-7 hybridoma-derived TsF2 or BW5147 tumor 
cell-derived  ascites  fluid  for  2  h,  washed  three  times,  resuspended  in  HBSS,  and  injected 
intravenously as activated Ts3 cells. 
Absorption of TsF2 with pTs3 Hybridomas.  0.5 ml of 1:20 diluted Ts2-derived ascitie factor was 
incubated with 5 ×  106 pTs~ hybridoma or BW5147 tumor cells for 1 h on ice with intermittent 
mixing. The supernatants were then centrifuged and tested for suppressor activity at a  1:200 
dilution. 
Adsorption and Elution of TsF.  The methods of absorption and elution of TsF using protein- 
conjugated Sepharose 4B columns were described in detail previously (7). 
Assay for Suppressive Activity of TsF on NP-mediated CS Responses.  The assay for NP-specific CS 
responses is also described elsewhere (23). Briefly, each animal was primed subcutaneously with 
2 mg of NP-O-Su in DMSO. 24 h later, the mice were treated with an intraperitoneal injection 
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otherwise, the hybridoma factors were tested in the effector phase, 5 or 6 d after priming. 0.4 
ml of each hybridoma supernatant or BW5147 control supernatant was injected intravenously 
on  the  day  before  and  the  day  of antigen  challenge.  6  d  after  immunization,  mice  were 
challenged in the left footpad with 0.025 ml phosphate~buffered saline (PBS) solution containing 
30/~g of NP-O-Su (prepared by mixing 25/~1 of a 2% NP-O-Su/DMSO solution in 0.4 ml PBS). 
Footpad swelling was measured 24 h after challenge. Swelling was determined as the difference, 
in units of 10 -3 cm between the left and right footpad thicknesses. 
Assay for Suppressive Activity of Activated NP-primed Lymph Node Cells.  Recipient mice were 
primed subcutaneously with 2 mg NP-O-Su. 24 h later, they were treated with an intraperitoneal 
injection of 20 mg/kg CY in saline. On day 6, they were given 1 ×  10  v NP-primed lymph node 
cells activated with C3H.SW-Ts2-7-derived TsF2 or BW5147 tumor cell-derived control factor. 
After transfer each  rnouse was challenged in the footpad with NP-O-Su as described above. 
Footpad swelling was measured 24 h after challenge. 
DNFB CS Responses.  CS was induced by two daily paintings on the shaved abdomen with 
25/~1 of 0.5% DNFB solution in acetone/ol{ve oil (4:1)  (4). 6 d after the last painting, 20 p,1 of 
0.2% DNFB in the same vehicle was applied to the left ear, and the ear swelling was measured 
as the difference between the left and right ear thicknesses. 
Percent Suppression.  The percent suppression was calculated by the following formula: percent 
suppression =  100  X  [(swelling of BW tumor supernatant-injected group -  swelling of TsF- 
injected group)/(swelling of BW tumor supernatant-injected group  -  swelling of unprimed 
group)]. 
Data Analysis.  Statistical analysis of the  experimental data with  respect  to  controls was 
calculated using the two-tailed Student's t test. 
Results 
pTsa  hybridoma  cells  were  prepared  by  the  fusion  of antigen-primed  Tsa  cells 
enriched  from  an  antigen  plate with  the AKR-derived BW5147  thymoma.  2-3  wk 
after fusion,  230  of 2,000  wells developed hybridoma colonies.  Each  of the colonies 
was screened for the presence of Npb-related idiotypic determinants and I-J determi- 
nants  by  microcytotoxicity testing.  60  lines were  selected that  bore  either  of these 
determinants but failed to constitutively secrete TsF3. The B6-derived cell lines were 
cultured in the presence of B6-Ts2-28 factor while the CKB  lines were cultured for 2 
d  in the presence of CKB-Ts2-59 factor. The cells were then washed three times with 
HBSS, and resuspended into fresh hypoxanthine-aminopterin-thymidine media and 
cultured for  1 d. The culture supernatants were tested for suppressive activity during 
the effector phase  of the  CS  response.  The  B6-pTs~-9  and  CKB-pTs3-80  lines were 
shown  to have specific suppressor activity (Table I).  Each  of these lines was cloned 
and subsequent  experiments were performed with the cloned hybridoma cell lines. It 
should be noted that both of these pTs3 cell lines initially reacted with both anti-I-J 
and  anti-NP  b  antisera;  however,  after  prolonged  culture  it  became  increasingly 
difficult to demonstrate the presence of these determinants on the cell lines. To ensure 
that  we were  not  assaying the suppressive activity of contaminating TsFz that  may 
have  been  carried  over into  the  second  culture,  suppressive activity was  assayed in 
CY-treated  mice  that  are  refractory  to  TsF2  (18)  (Table  I).  The  data  in  Table  I 
emphasize  that  pTs3  ceils must  be  activated to  release a  specific suppressor  factor. 
The  specificity of these  pTs3-derived  factors  is  demonstrated  by  their  inability to 
suppress DNFB CS responses in animals that were primed and challenged with DNFB 
(Table I). 
Kinetics  of pTs3  Hybridoma Activation.  The  cloned  B6-pTs3-9  and  CKB-pTsa-80 
hybridoma cells were cultured with suppressor factor derived from B6-Tsz-28 or CKB- 
Ts2-59 cells, respectively, or with BW5147-derived control 'factor' for various intervals MINAMI, OKUDA,  FURUSAWA,  AND  DORF 
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Recipient  Antigen  CY treat- 
strain  priming  ment 
TsF Source  CS response:]: 
Hybridoma  TsF2 used for  NP-O-Su  DNFB 
cells  activation 
10  -3 cm + SE 
C57BL/6  +  +  BW5147  B6-Ts2-28  25.8 ±  2.3  9.5 ~  1.6 
C57BL/6  +  +  B6Ts2-28  --  27.0  ___ 3.4  ND§ 
C57BL/6  +  -  B6-Ts2-28  --  16.3 +_ 2.81{  ND 
C57BL/6  +  +  B6-pTsa-9  --  23.6 +  1.2  ND 
C57BL/6  +  +  B6-pTs~-9  B6-Ts2-28  9.8 +  1.01{  9.5 +  1.2 
C57BL/6  -  +  --  --  4.8 ±  1.6  1.3 :tz 0.6 
B10.A  +  +  BW5t47  --  42.6 +  2.1  9.3 +  0.8 
B10.A  +  +  CKB-Ts2-59  CKB-Ts2-59  41.8 :t: 4.2  ND 
B10.A  +  -  CKB-Ts2-59  --  17.6 +  1.811  ND 
B10.A  +  +  CKB-pTsa-80  --  39.5 ±  3.1  ND 
B10.A  +  +  CKB-pTs~-80  CKB-Ts2-59  16.5 ±  2.411  11.2 ±  0.611 
B10.A  -  +  --  --  11.8 +  0.8  0.5 ±  0.3 
* Groups of four or five mice were immunized with either NP-O-Su or DNFB. 24 h later some groups were 
given 20 mg/kg CY i.p. On the day before and the day of antigen challenge, mice were given an injection 
of 0.4  ml i.v.  of either control  BW5147  or suppressor factors.  Activated  pTsa suppressor factors were 
obtained by culturing pTs3 hybridomas with TsF2 for 2 d and then in fresh media for l  d. 
$ The data are expressed as the increment of footpad or ear swelling. 
§ Not done. 
[I Indicates significant suppression, P <  0.01. 
L_ 
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Fro.  1.  Kinetics of pTs3 activation.  Groups of B6 mice or B10.BR  mice were immunized subcu- 
taneously with NP-O-Su. 24 h later all mice were given 20 mg/kg CY Lp. During the effector phase, 
mice were given an injection  of 0,5  ml i.v.  of either BW5147  or activated  suppressor hybridoma 
factors. Activated B6-pTs~-9  (D) and CKB-pTsa-80 (U) factors were obtained by culturing suppressor 
hybridomas with B6-Ts2-28 ascites or CKB-Ts2-59 ascites,  respectively, for 30 rain to 48 h, and then 
in fresh media for I d. The data represent the pooled results from two separate experiments in the 
case of CKB-pTss-80 and one experiment with B6-pTs3-9.  The data are expressed as the percent 
suppression of the NP-O-Su CS response compared with BW5147 supernatant controls (- -  -). 
ranging  from  5  rain to 48  h. The  hybridoma  cells were washed  and  cultured  in fresh 
media  for  24  h,  and  the  latter  culture  supernatants  were  assayed  for  suppressive 
activity in NP-O-$u-primed  CY-treated  B6 or B10.BR  recipients. As shown  in Fig.  1, 
maximal  suppressive  activity was noted  after 6-24  h  of in vitro activation  with  TsF2. 1384  INDUCIBLE HYBRIDOMA SUPPRESSOR  CELLS 
Activation of pTsa hybridomas with TsF2 for up to 48 h  did not result in increased 
levels of immune suppression. Over a  large series of experiments we noted that  the 
level  of suppression  obtained  with  pTsa-derived  factors  ranged  from  30  to  90%; 
however most batches of pTsa-derived factor caused about 50-60% suppression. 
Effector Phase Suppression.  To compare the kinetics of activity of the pTsa-derived 
suppressor factors with other NP-specific suppressor factors, we determined when in 
the phase of the  immune response the pTsa hybridoma-derived factors were active. 
0.5 ml of pTsa- or Tsl-derived factor was injected intravenously (a) on the day of and 
the day after antigen priming (induction phase) or (b) the day before and the day of 
antigen challenge (effector phase). The groups of mice that received control BW5147 
or pTsa-derived factors were injected intraperitoneally with 20 mg/kg CY on the day 
after antigen priming. In confirmation of previous reports  (7,  18),  the B6-Tsa-29 and 
CKB-Tsl-17-derived TsF1 only demonstrated suppressive activity when administered 
during the induction phase of the immune response (Table II). In contrast, activated 
B6-pTsa-9- and  CKB-pTsa-80-derived factors  were  only active  when  administered 
during the effector phase of the NP response (Table II). 
Genetic Restrictions on pTsa-derived Factors.  Since the cell surface phenotype of pTsa 
cells  and  the  kinetics  of activity  of pTsa-derived  factors  correlated  with  those  of 
conventional and hybridoma Tsa cells and factors, we wished to further explore the 
similarities between these ceils by evaluating the genetic restrictions on the activity of 
pTsa-derived factors.  B6-pTsa-9 and CKB-pTsa-80 cells were activated with B6- and 
CKB-derived TsFa, respectively. Control BW5147 cells were also cultured in TsF2 for 
2  d,  after  which  the  cells  were  washed  and  recultured  in  fresh  medium.  The 
TABLE  II 
p Tsa-derived Factor Suppresses the Effector Phase of the CS Response* 
Recipient strain 
Footpad swellingS: 
CY treat-  Factor source  Time of TsF administration  ment 
Induction phase  Effector  phase 
C57BL/6 
10  -a cm +_ SE 
+  BW5147  36.4 ± 2.0  36.4 + 2.0 
--  B6-Ts,-29  16.0 _+ 2.1§  N.D.Ip 
+  B6-pTsa-9.3  activated with  39.3 ± 0.9  13.5 --_ 2.4§ 
B6-Ts2-28 factor 
BI0.A  +  BW5147  45.6 --- 1.6  45.6 +  1.6 
-  CKB-Tsl-17  13.3 ± 2.7§  43.8 ± 2.6 
+  CKB-pTsa-80.2  activated with  45.0 ± 2.2  21.3 -+ 1.9§ 
CKB-Ts2-59 factor 
* 0.5 ml of TsFl, pTsa or control BW5147 supernatants were given intravenously on the day of and the day 
after NP-O-Su priming (induction phase) or the day before and /he day of NP-O-Su challenge (effector 
phase). Appropriate groups were treated with CY to prevent Tss generation (groups which received TsF1 
could not be CY treated since these factors fail to suppress CY-treated recipients). Four or five mice were 
included in each group. 
~: The negative control values, representing the swelling  observed in unprimed C57BL/6 and B 10.A mice, 
were 7.3 --- 0.5 and 9.2 +  1.0, respectively. 
§ Indicates significant suppression,  P < 0.01. 
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supernatants  from  these activated cells were tested for their ability to suppress NP- 
induced CS responses in various strains of mice. The data from several experiments 
are summarized in Table III. In brief, suppressor factors derived from activated B6- 
pTs3-9 cells only suppress  NP  responses  in  H-2-  and  Igh-compatible B6  recipients. 
Similarily, suppressor factors from activated CKB-pTs3-80 cells only function in CKB 
recipients.  Thus,  matching  at  both  the  H-2  and  Igh  complexes  was  required  for 
expression ofpTs3-derived TsF activity. Mismatching the pTs3 donor and the recipient 
strain for either H-2 or Igh was sufficient to prevent expression of suppressor activity. 
Thus,  CKB-pTss-80-derived factors suppress NP-induced  CS responses in CKB  (H- 
2 k,  Igh  b)  mice  but  not  in  Igh-congeneic C3H  recipients  (H-2  k,  IghJ).  Furthermore, 
suppressor factors derived from activated B6-pTs3-9 cells functioned in B6 (H-2  b) mice 
but not in H-2-incompatible B 10.G (H-2  q) recipients (Table III). 
To further establish the role of H-2 in restricting pTs3-derived TsF activity, a  series 
of H-2-congeneic strains were used as recipients (Table IV). All the strains carried H- 
2  recombinant  haplotypes  in  which  various  regions  were  of  H-2  b  origin,  thereby 
enabling precise intra-H-2  mapping of the genes responsible for genetic restriction. 
The data demonstrate the role of the I-J region in controlling the restrictions on the 
activity of pTsa-derived factors. Thus, when B6 (I-Jb)-derived pTs3 factor was assayed 
in I-J-compatible 4R and 3R recipients, significant levels of suppression were observed. 
However, the same batch of pTs3-derived factor failed to suppress NP responses in I- 
jk-bearing 5R or B 10.MBR recipients (Table IV). In reciprocal experiments CKB  (I- 
Jk)-derived pTs3 factor suppressed NP responses in B 10.MBR and 5R recipients, but 
not  in  3R  or  4R  mice  (Table  IV).  The  critical  role  of  the  I-J  region  is  clearly 
established by the reciprocal patterns of pTs3 activity noted in I-J-congeneic 3R and 
5R animals (Table IV). 
Specificity of Ts3 Activation.  The next series of experiments was designed to evaluate 
the nature of the signals required for activation of pTs3 cells, pTs3 cells were incubated 
with  hybridoma-derived TsFz or control BW5147  ascitic fluid  (Table V).  After 2  d 
the cells were  washed  and  recultured  in  fresh  media for an  additional 24  h.  These 
TABLE  III 
Genetic Restrictions  of Activated p Ts3-derived Factors* 
Factor source 
Footpad swelling in recipient strains 
C57BL/6  B10.G  C57L  C3H  CKB 
(H-2  b, Igh  b  (H-2  q  , Igh  b  (H-2  b, Igh")  (H-2  k  , Igh  j)  (H-2  k  , Igh  b) 
10  .3 cm +_ SE 
BW5147  30.3 + 2.1  35.6 + 2.0  32.8 ±  7.0  36.6 ± 3.1  41.6 ± 4.1 
B6-pTs3-9  16.0 ±  1.6:~  39.4 ± 2.8  32.0 ± 4.4  35.8 + 5.3  43.5 ± 4.1 
CKB-pTsa-80  32.4 ± 4.0  40.6 ± 3.7  ND§  33.3 ±  3.1  16.0 +  1.5:~ 
Negative control  8.7 ± 0.8  8.3 ±  1.4  7.2 ± 2.0  7.1 ±  1.7  8.0 ±  1.3 
* The data from two to four independent experiments were pooled. Each group contains 7-I3 mice, which 
were immunized with NP-O-Su. 24 h later all groups were given 20 mg/kg cyclophosphamide i.p. On the 
day before and the day of antigen challenge (effector phase), mice were given an injection of 0.4 ml i.v. 
of either control  BW5147 or activated pTsa hybridoma factors. Activated pTs3-derived factors were 
obtained by culturing B6-pTs3-9 or CKB-pTs2-80 hybridoma with  B6-Ts2-28 or CKB-Ts2-59-derived 
factor respectively for 2 d and then in fresh media for 1 d. 
:~ Indicates significant suppression, P < 0.001. 
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TABLE IV 
Intra-H-2 Mapping of the Restrictions on Activated p Ts3 Hybridoma-derived Factors* 
TsF source 
NP-0-  TsF2 for activa-  Su  tion  priming 
Footpad swelling  in recipient strains 
B10.A (3R)  B10.A  (4R)  B10.A  (5R)  BI0.MBR 
10  .3 cm + SE 
BW5147  --  +  48.3 +  1.8  28.2 + 2.2  30.2 ±  1.8  40.2 --- 0.8 
B6-pTsa-9  B6-Ts2-28  +  29.0 + 2.0~:  15.3 ±  1.0~  29.0  + 0.7  41.0 ±  1.3 
CKB-pTss-80.1  CKB-Ts2-59  +  48.0 ± 3.2  27.8 -- 2.1  19.0 ... 1.0:~  27.5 ___ 1.8:~ 
CKB-pTss-80.2  CKB-Ts2-59  +  46.7 + 2.0  28.5 +- 1.0  21.5 ±  1.21:  31.3 + 2.3:}: 
BW5147  --  -  10.3 ±  1.7  6.3 --- 0.9  8.3 +  1.3  12.3 ± 0.9 
* Groups of four or five mice were immunized with NP-O-Su. 24 h later all groups were given 20 mg/kg 
CY i.p. On the day before and the day of NP-O-Su challenge, mice were given an injection of 0.5 ml i.v. 
of either control BW5147 or activated pTss hybridoma factors, pTsa factors were obtained by culturing 
pTsa hybridomas with TsFz for 2 d and then in fresh media for I d. Two different subclones of CKB- 
pTss-80 were tested in this experiment. 
:I:'Indicates  significant suppression,  P < 0.0l. 
activated pTsa culture supernatants were tested for suppressive activity in NP-primed 
B6,  B10.BR,  or  C3H.SW  CY-treated  recipients.  Significant  levels  of  suppressive 
activity were only noted in those combinations in which the H-2 and Igh determinants 
of the TsFz, pTs3 cells and the recipient strains were matched. Thus, B6 (H-2  b, Ighb) - 
derived B6-pTsa-9 cells were activated after incubation with TsF2 factors from either 
B6-derived B6-Ts2-28 or B6-Tsz-14 cells, but incubation with TsF2 derived from an 
H-2-mismatched,  Igh-matched  CKB  (H-2  k,  Igh  b)  source  or  an  H-2-matched,  Igh- 
mismatched C3H.SW source failed to trigger the release of suppressive materials from 
pTs3 cells (Table V). In accord with the data presented in the previous section, factors 
from  activated B6-pTss-9 cells failed to suppress  H-2- or Igh-incompatible B10.BR 
(H-2  k, Igh  b) or C3H.SW (H-2  b, Igh  j) recipients. Furthermore, supernatants from B6- 
pTss-9 cells incubated with CKB- or C3H.SW-derived TsF2 also failed to function in 
B10.BR or C3H.SW recipients. Thus, homology between the TsF2 and the recipient 
strain is not sufficient for expression of suppressive activity. The combined data imply 
that  H-2 and Igh homology is required at  two stages:  (a)  for the activation of pTsa 
cells and (b)  for the expression of the suppressive activity mediated by pTss-derived 
factors. To verify these conclusions, the genetic restrictions on the activation of CKB- 
derived pTs3 cells were analyzed in reciprocal fashion with similar results (Table V). 
As an additional control the  biological activity of the  C3H.SW-Ts2-7-derived TsF2 
was established by incubation with a population of NP-primed C3H.SW lymph node 
cells. As expected from our previous reports  (17,  19),  the C3H.SW-derived TsF2 was 
capable  of activating the  Tsa  cells  in  this  lymphocyte population.  Finally, we  at- 
tempted to activate B6-pTs3-9 cells with a  mixture of Ighb-compatible CKB-derived 
TsFz and H-2-compatible C3H.SW-derived TsFz. The mixture of these two functional 
TsF2 factors failed to activate B6-derived pTs3 cells (Table V). 
Ability of pTsa  Cells to Adsorb I-J-mismatched  TsF2.  One possible explanation for the 
failure of Igh- or H-2-mismatched TsFz to activate pTsa cells is that  these products 
will not bind the pTs3 cells. In fact, we have previously demonstrated that monoclonal 
TsF2 has antiidiotypic specificity and will only bind to cells that carry the appropriate 
idiotypic determinants (15). In the present studies, we evaluated the ability of TsFz to MINAMI,  OKUDA,  FURUSAWA,  AND  DORF 
TABLE  V 
Specificity of  p Tsa Hybridoma Activation* 
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Strain of CY-  Normalized per- 
treated recipients  pTsa or Ts3 source  TsF source  cent suppression 
+  sE~ 
C57BL/6  BW5147  None  0 +  4 
B6-pTs3-9  BW5147  5 --- 7 
B6-Ts2-28  49 --+_ 5§ 
B6-Ts2-14  58 ±  1§ 
CKB-Ts2-59  8 +  3 
C3H.SW-Ts2-7  8 +  4 
CKB-Ts2-59 +  C3H.SW-Ts2-7  3 --- 4 
CKB-pTs8-80  BW5147  -6 "4- 3 
B6-Ts2-28  -3 +  5 
CKB-Ts2-59  -3 +  6 
B10.BR  BW5147 
B6-pTss-9 
CKB-pTsa-80 
None  0 -+ 6 
BW5147  -6+__ 13 
B6-Ts2-28  0 +- 6 
B6-Ts2-14  3 +  9 
CKB-Ts2-59  --6 ±  13 
C3H.SW-Ts2-7  -3 +- 14 
BW5147  7 +- 4 
B6-Ts2-28  -5 +-. 8 
B6-Ts2-14  -  1 --4 7 
CKB-Ts2-59  60 +5§ 
C3H.SW-Ts2-7  -5 +  2 
C3H.SW  BW5147  None  0 +  3 
B6-pTsa-9  B6-Ts2-28  -4 +  3 
C3H.SW-Ts2-7  4 :tz 9 
CKB-pTsa-80  CKB-Ts2-59  -  1 +  8 
C3H.SW-Ts2-7  0 +  2 
C3H.SW 
NP-primed Tss[]  BW5147  0 +  9 
C3H.SW-Ts2-7  68 +- 9§ 
* Recipient mice were immunized with NP-O-Su. 24 h  later all mice were given 20 mg/kg CY i.p. On the 
day before and the day of antigen challenge, mice were given 0.4 ml i.v. of either BW5 t47 or activated 
suppressor hybridoma factors. Activated pTsz-derived factors were obtained by culturing B6-pTss-9 or 
CKB-pTs3-80 hybridoma cells with various kinds of TsF2 for 2 d  and then in fresh media for  1 d. 
$ The data represent the pooled results from six separate experiments (not all groups were included in each 
experiment). The data were normalized and the percent suppression +  standard error was calculated. 
Each group represents the pooled normalized data of at least two experiments involving a total of at least 
seven mice. 
§ Indicates significant suppression, P <  0.01. 
[[ Regional lymph node cells from C3H.SW mice primed subcutaneously with 2 mg NP-O-Su 6  d  earlier 
were cultured in vitro with C3H.SW-Ts2-7 ascitic factor or control BW5147 factor for 2 h. After washing, 
1 ×  107 activated C3H.SW  lymph node cells were transferred into CY-treated C3H.SW mice primed 
with NP-O-Su. 
bind  to  I-J-mismatched  pTsa  cells. Thus  aliquots  of B6- and  CKB-derived  TsF2  were 
adsorbed  with  3  ×  107  B6-pTs~-9,  CKB-pTsa-80,  and  BW5147  cells/ml.  The  activity 
of  the  absorbed  TsF2  was  assayed  on  NP-O-Su-primed  recipients.  As  indicated  in 
Table  VI,  TsF2  activity  was  completely  absorbed  by  both  H-2-compatible  and  H-2- 1388  INDUCIBLE  HYBRIDOMA  SUPPRESSOR  CELLS 
TABLE  VI 
Absorption ofTsFzwith  I-J-mismatchedpTsaCel~* 
Recipient strain  NP-O-Su  TsF source  Cells for TsF2 absorp-  Footpad swelling 
priming  tion 
C57BL/6 
10  acm ± SE 
+  BW5147  --  43.5 +  2.7 
+  B6-Tsz-28  BW5147  18.3 ±  0.3~ 
+  B6-Ts2-28  B6-pTsa-9  46.3 +  1.3 
+  B6-Ts2-28  CKB-pTsa-80  45.5 ±  1.9 
-  None  --  3.3 ±  0.7 
B10.BR  +  BW5147  --  40.0 +  2.2 
+  CKB-Ts2-59  BW5147  23.3 +  1.2:~ 
+  CKB-Tsz-59  B6-pTsa-9  38.0 ±  3.3 
+  CKB-Ts2-59  CKB-pTsa-80  37,8 ±  3.2 
-  None  --  9,0 ±  1.2 
* Aliquots of TsFz were absorbed with 2.5 X  10  ° B6-pTs3-9  (I-Jb), CKB-pTs3-80  (I-jk), or control BW5147 
cells/ml. The  absorbed TsF2 was then  tested for effector phase suppressive activity in previously NP-O- 
Su-primed recipients. 
:~ Indicates significant suppression, P <  0.00l. 
TABLE  VII 
Fractionation of  p Tsa-derwed Factors on Immunoadsorbent Columns* 
Footpad swelling 
Immunoad- 
Column 
Factor source  sorbant  fraction  Source of suppressor factorZ~ 
column 
B6-pTsa-9  CKB-pTs3-80  B6-Ts3-8 
Activated BW5147 
Nonactivated pTs3 
Activated pTsa 
Negative (background) 
controls 
10  -3 cm + SE 
None  --  34.8 _  2.0  50.2 +  2.6  29.5 +  2.0 
None  --  35.2 +  3.4  50.4 +  3.4  16.8 +  1.3:~ 
None  --  13.6 +  1.4:~  16.2 +  2.3~  -- 
Anti-I-J  b  Filtrate  40.0 +  1.1  31.3 +  3.8:~  28.3 -  1.7 
Eluate  17.5 +  4.3z~  43.0 +  4.0  17.0 +  1.2:~ 
Anti-I-J  k  Filtrate  14.4 +  1.3z~  47,8 +  4.4  18.3 +  1.6z~ 
Eluate  34.0 +  4.0  21.3 _  1.5~  30.3 +  3,2 
NP-KLH  Filtrate  44.3 +  4,2  47.0 +  2.0  30,5 +  2.2 
Eluate  18.5 +  5.5:~  19.3 +  3.3~  15.8 +  3.0:~ 
Anti-NP  b  Filtrate  43,0 +  3.5  43.3 ±  6.9  25,5 ±  3.7 
Eluate  21.8 ----- 1.8:~  19.3 ±  3.3:~  17.3 +--  1.3:~ 
NP  u  Filtrate  9.8 ±  2.0:~  31,3 ±  3.8:~  16.3 ±  1.9:~ 
Eluate  30.4 ±  2.4  43,0 +  4.0  27.8 ±  1.7 
--  --  8.3  ±  3.4  9.2 +  2.5  10.0 ±  1.6 
* Activated pTsa or conventional nonactivated Ts3 hybridoma-derived TsF containing supernatant  fluids 
were adsorbed onto various columns and the filtrate and acid-eluted fractions were tested for suppressive 
activity  in  either  C57BL/6  or  BI0.BR  recipients.  The  TsF3  from  the  constitutatively secreting  Ts3 
hybridoma (B6-Tss-8)  is included for comparison. Refer to the legend to Table I  for protacol. 
Indicates significant suppression, P  <  0.01. 
incompatible  pTs3  cells.  Thus  it appears  that  TsF2  can  bind  to  Z-J-mismatched  pTsa 
cells but  that  this  binding  event  is insufficient  to cause  activation  of the  pTs3  cell. The 
specificity  of absorption  was  demonstrated  by  the  inability  of BW5147  cells to  absorb 
TsF2  activity  (Table  VI). MINAMI, OKUDA, FURUSAWA, AND  DORF 
TABLE VIII 
Presence of TsF in Extracts of Nonactivated p Tsa Hybridoma Cells* 
Normalized  TsF2 used for acti-  pTs3 source  vation  Fraction  percent CS sup- 
pression ± SE 
BW5147  None  Cell extract  0 ± 8 
CKB-pTsa-80  None  Cell extract  56 + 6:]: 
CKB-pTs3-80  None  Supernatant  8 ± 9 
CKB-pTs3-80  CKB-Ts2-59  Cell extract  2 + 9 
CKB-pTs8-80  CKB-pTs2-59  Supernatant  40 + 5~ 
BW5147  None  Cell extract  0 ± 6 
B6-pTss-9  None  Cell extract  61 +  7~ 
B6-pTss-9  None  Supernatant  -  12 ± 9 
B6-pTss-9  B6-Ts2-28  Cell extract  27 ±  7 
B6-pTss-9  B6-Ts2-28  Supernatant  40 4- 10:~ 
* TsF2-activated  (see Table I  for protocol) or nonactivated  pTs3 cells were 
disrupted by three  to  four  cycles of freeze-thawing;  the cell  debris  was 
removed by centrifugation and the extract fraction was tested for suppressive 
activity. Supernatant fractions represent aliquots of the culture supernatants 
from the activated or nonactivated  cells before disruption.  The data from 
two  experiments  were  normalized  and  expressed as  percent  suppression. 
Groups consist of seven to ten mice. 
Indicates significant suppression, P < 0.05. 
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Characterization  ofpTss-derived  Factors.  To  further  document  the  relationship  be- 
tween  pTss-  and  Tss-derived  factors,  the  antigeneic  determinants  present  on  the 
factors were analyzed using a  series of affinity columns.  As shown  in Table VII, the 
factors derived from activated pTs3 cells carried allele-specific I-J determinants. Thus 
passage  of B6-pTsa-9  factor  over  anti-I-J  b  immunoadsorbants  depleted  suppressive 
activity. The  suppressive activity could  be  recovered  from  the  anti-I-J  b column  by 
acid elution (Table VII). Furthermore, the specificity of adsorption was illustrated by 
the inability of anti-I-J  k immunoadsorbant columns to deplete the B6-pTss-9-derived 
suppressor activity. In  reciprocal experiments  the CKB  (H-2k)-derived pTs3  factors 
were removed on anti-I-J  k columns and the activity was recovered in the acid eluates. 
In addition to I-J determinants  the pTss-derived factors have  NP  b idiotype-related, 
antigen-binding  determinants.  Thus  both  the  B6-  and  CKB-derived  pTs3  factors 
could  be  adsorbed  onto  and  eluted  from  antiidiotype  (anti-NP  b)  or  antigen  (NP- 
KLH) immunoadsorbants  (Table VII). To demonstrate that the pTss-derived factors 
did not require any residual TsF2 for expression of activity, we passed the factors over 
columns that contained NP  b idiotype; these columns had been shown  to completely 
deplete TsF2 activity (15). pTsa factors failed to bind to NP  b idiotype-coupled columns. 
For further comparison, the results of the pTs3 fractionation are compared with the 
fractionation  of conventional TsF3  from  an  NP-specific hybridoma  (B6-Tss-8)  that 
constitutatively secretes TsF3 (Table VII). 
Presence of Preformed TsF3 in p Ts3 Cells.  The final series of experiments was directed 
at determining whether activation of pTs3 cells caused the de novo synthesis of TsF3 or 
if TsF3 was already stored in these cells and activation resulted in the export of this 
factor  into  the  surrounding  medium.  Nonactivated  CKB-pTsa-80  and  B6-pTss-9 
hybridoma cells were  disrupted by freeze-thawing and  the cell extract was  injected 
into NP-primed CY-treated CKB  and  B6  recipients, respectively. These extracts of 
nonactivated pTs3 cells contained suppressive activity whereas extracts from BW5147 1390  INDUCIBLE HYBRIDOMA SUPPRESSOR CELLS 
control ceils failed to suppress  NP-induced  CS responses  (Table VIII). The antigen 
specificity of the extracted  factor was established by determining that  this material 
did  not  suppress  DNFB-induced  CS  responses  (data  not  shown).  As  additional 
controls, the culture media in which the nonactivated pTsa cells were grown was also 
tested for suppressive activity. As expected, supernatants from nonactivated pTsa cells 
failed to suppress NP CS responses. 
In addition, pTsa cells that had been activated by TsF2 and then allowed to release 
factor for 24  h  in  fresh medium were disrupted  and  the cellular extracts tested  for 
suppressive activity. Little or no suppressive activity was demonstrable in the extracts 
of activated pTsa cells (Table VIII). As expected, the supernatants of activated pTsa 
cells contained suppressive activity. 
Discussion 
The pTsa hybridomas described in this report display numerous similarities to the 
Tss cells previously described in the NP system. The origin, phenotype, and activation 
requirements  of  the  pTsa  cells  as  well  as  the  genetic  restrictions  and  antigenic 
determinants  found on pTsa hybridoma-derived factors are identical  to those previ- 
ously noted on conventional Ts3 cells and factors (4,  5,  17-19).  Thus, the pTsa and 
Tsa hybridomas were derived  from the  fusion  of antigen-adherent  T  cells obtained 
from immune mice. Tsa and  pTsa cells and  their  factors bear I-J- and  NPLrelated 
idiotypic  determinants.  The  factors only  function  during  the  effector phase of the 
immune response and can suppress CS responses in CY-treated recipients. The activity 
of the suppressor factor is restricted by at least two sets of genes, one associated with 
the I-J region and the other with the Igh complex. In view of all of these similarities, 
we have termed these hybridoma cells, pTsa. The prefix denotes that the cells must be 
specifically activated to release their biologically active product. This feature clearly 
distinguishes this series of hybridomas from those which constitutively release TsFa. 
These inducible hydridomas presumably represent a stable stage in the differentia- 
tion  cycle of Tsa cells,  i.e.,  a  resting,  nonsecretory stage of the mature Tsa cell.  We 
have previously noted that after conventional antigen-priming, Tsa cells are generated 
concomitantly with helper and CS effector T  cells. However, the mature Tsa cells will 
not mediate suppressive activity unless specifically activated by TsF2. Thus, mature 
Tsa  populations  normally  remain  in  an  inactive  resting  state,  thereby  allowing 
expression of helper or CS activity. However, after release of TsF2, activation of Tsa 
cells  and  suppression  occur.  This  process  allows  for a  rapid  regulation  of immune 
responses. The establishment of an inducible hybridoma line confirms these conclu- 
sions, which were originally hypothesized after analysis of the activation of heteroge- 
neous populations of splenic or lymph node Tsa cells.  The latter lymphocyte popula- 
tions contained Tsa cells as well as other NP-specific T  cells including helper and/or 
CS effector cells. The present  report describes hybridoma clones that have retained 
the  properties  of a  mature,  non-TsFa-secreting  Tsa  cell.  Furthermore,  this  report 
directly documents the interaction of TsF2 with Tsa cells. 
Other investigators (24-26)  have described an analogous series of major histocom- 
patibility  complex  (MHC)-restricted  hybridoma  or  cloned  T  cells  that  represent 
inducible helper or proliferating cells. Activation of these hybridomas or clones also 
requires corecognition of two components, i.e., antigen and I-A- or I-E-encoded MHC 
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ognition of two elements:  MHC  components encoded by the  I-J  subregion  and  a 
specific T  cell-derived idiotype (which may also be regarded as an antigenic deter- 
minant or internal image). The genetic restrictions and the mixing experiment used 
to analyze the activation of pTs3 hybridomas indicated that both I-J and idiotypic 
determinants  must  be present  on  the  same  molecular complex.  Similar  activation 
requirements were  noted  for cloned or hybridoma helper T  ceils,  which  required 
presentation of MHC products and antigenic determinants on the same cell. Thus, 
similar  principles  apply  for  the  activation  of both  helper  and  suppressor  T  cell 
populations. However, it appears that cells of the suppressor cascade are programmed 
to recognize or interact with I-J molecules whereas helper cells interact with I-A or 
I-E molecules. 
Taniguchi  and  associates  (27)  have also  identified an  I-J-positive inducible sup- 
pressor cell hybridoma that was obtained after fusion of antigen-adherent cells from 
KLH-primed mice. These hybridoma cells bore a  receptor (acceptor)  for a  KLH- 
specific suppressor factor (27).  After activation with suppressor factor, the inducible 
hybridoma  described  in  the  KLH  system  produced  its  own  distinct,  genetically 
restricted factor that displayed carrier specificity. However, the factors produced by 
the latter inducible suppressor cell hybridoma had different binding properties than 
those described in the present report. Thus, Taniguchi et al.  (27)  demonstrated that 
the suppressor  factor that  was  required to activate hybridoma pTs cells bound  to 
KLH whereas the factor released from pTs cells failed to bind to KLH. Furthermore, 
the authors concluded that the pTs-derived factor was antiidiotypic, since it bound to 
other T  cell  hybridomas  that  presumably  bore idiotypic determinants  specific for 
KLH (27). The data described in this report represent a reciprocal pattern. Thus, in 
the NP system, the TsF2 factor required for pTs3 activation bound to idiotype while 
the pTsa-derived factor bound to antigen. Several hypotheses can reconcile the latter 
two series of observations. (a) These pTs hybridomas represent distinct elements of a 
common suppressor cell cascade.  Presumably, the TsFa released by pTsa cells could 
activate a complimentary antiidiotypic suppressor T cell (Ts4) similar to that described 
by Taniguchi et al.  (27).  (b)  Both idiotypic and antiidiotypic Ts2 and Ts3 cells and 
factors exist. Kapp and Araneo  (13)  have interpreted data in the L-glutamic acid  5°- 
L-tyrosine  s° system in support of this contention. The method of Ts induction and the 
possibility of antigen bridging would presumably determine the idiotypic or antiidi- 
otypic  nature  of  the  different  suppressor  elements.  (c)  Perhaps  two  distinct  Ts 
pathways are involved. This would imply that  the suppressor cells described in the 
NP and KLH systems are members of independent suppressor cell pathways. 
The identification of inducible T  cell hybridomas permits analysis of the activation 
processes required for suppressor cell function. Although the activation of pTs3 cells 
requires triggering with ascites containing TsF2, additional requirements for activation 
may also exist. Thus, it is possible that the ascites contains additional substances that 
are involved in pTsa activation.  Nonetheless, the  data demonstrate  that  pTs3 cells 
require specific activation with TsF2. Furthermore, analysis of the genetic restrictions 
on pTs3 cell activation indicated that the H-2 and Igh complexes of the donor had to 
match the strain from which the pTs3 cells were derived. Homology at only one gene 
complex (H-2 or Igh)  was not sufficient to trigger activation of the pTs3 cells. The 
failure of Igh-matched H-2-mismatched TsF2 to trigger pTsa cells was not due to the 
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could completely absorb activity. These findings  suggest that  two distinct  steps are 
required  for  pTs~  triggering,  i.e.,  binding  of TsF2  to  the  idiotypic  receptor  and 
interaction  of the  cell  with  the  I-J  (or  anti-I-J)  determinant  on  TsF2.  These  two 
triggering signals must be delivered in a  very specialized spacial or temporal config- 
uration, presumably by a single molecule or molecular complex. Thus, incubation of 
pTs3 cells with two distinct TsF2 factors, one having H-2 homology and the other Igh 
homology, was  insufficient  for pTs3  activation.  The simplest  interpretation  of this 
observation is that the triggering of the receptor (acceptor) site on pTs3 cells requires 
activation by two spacially related  determinants.  Several laboratories  (28-33)  have 
demonstrated  that TsF from a  variety of sources is a  dimer that contains one chain 
with  MHC  (I-J)  determinants  and  another  with  antigen-binding  or  Igh-linked 
determinants.  The physiological significance for this type of molecular complex may 
lie in the mechanism required for suppressor cell triggering. 
Another  important  conclusion  that  can  be  derived  from  the  present  series  of 
observations is that antigen is not required for the triggering of pTs3 cells. In previous 
systems it was not possible to evaluate the requirements for antigen  in this phase of 
the suppressor cell cascade, since the Ts3 cells are obtained from antigen-primed mice 
and the assay for CS immunity requires the presence of antigen in the effector phase. 
However, the present  observations clearly demonstrate  that  antigen  is not  required 
for activation of pTs3 hybridomas and presumably is also not required  for activation 
of conventional Ts3 lymphocytes. 
It is also known that antigen  is not required  for Ts2 cell induction  (11,  21).  Thus, 
once  the  cellular  elements  of the  suppressor  cell  cascade  are  generated,  immune 
suppression can proceed in the absence of additional  antigen.  Antigen is apparently 
only required for the initial induction of Tsl and Ts3 cells (4,  19). Subsequent cellular 
activation presumably proceeds via idiotype antiidiotype and I-J anti-I-J interactions. 
Thus, the cascade of regulatory interactions observed in  NP systems conforms with 
the basic predictions of the Jerne network theory (34). 
In a  series of preliminary experiments, we tried to activate pTs3 hybridoma cells 
with  either  antigen,  antiidiotype,  or  anti-I-J.  Neither  NP-bovine  serum  albumin, 
antigen-modified syngeneic cells, guinea pig antiidiotype, auto-antiidiotype, or anti- 
I-J alloantiserum was able to activate the pTsa cells under the experimental conditions 
used  (data  not  shown).  Although  these  attempts to activate pTs3 cells were unsuc- 
cessful, the therapeutic value of identifying alternative mechanisms for Ts3 activation 
is potentially great for selected diseases. 
In addition it is important to distinguish among the mechanisms of TsF activation. 
As shown  in  this  report, TsFz acts on  a  previously expanded  and  at  least partially 
differentiated  population  of antigen-specific Ts3 cells, causing the release of soluble 
mediators.  In contrast,  the soluble  factors obtained  from first-order suppressor cells 
(TsF1)  induce the generation and differentiation of another suppressor cell population 
from normal  splenic  T  cells  (7,  8,  11).  Thus,  whereas TsFz activates, TsF1  induces 
suppressor cells. 
Finally, it is important  to note that the activation of pTs3 cells by TsF2 does not 
appear  to  involve  the  de  novo  synthesis  of TsF3.  Thus,  lysis  of nonactivated  pTs3 
hybridoma ceils released an antigen-specific suppressor factor that  functioned  in the 
effector phase of the CS  response. TsF3 had already been synthesized  by pTsa cells 
before  activation.  After TsF2  activation,  the  pTs3  cells  cleared  the  TsF3  from  the MINAMI, OKUDA, FURUSAWA, AND DORF  1393 
intracellular  pool  and  released  it  into  the  surrounding  medium.  Thus,  pTs3  cells 
represent a  mature differentiated stage in the life cycle of the Ts3 suppressor cell in 
which  a  specific activation step is required  for the rapid  (<6 h)  release of antigen- 
specific suppressor factors into the local environment. The ability of Tsa cells to store 
TsF3 permits the immune system to rapidly modulate immune responses. 
Summary 
The Tsa subset of suppressor cells is generated after antigen priming, but, in order 
to express suppressor activity these cells require an additional activation step involving 
triggering with specific suppressor factors (TsF2). This report characterizes two cloned 
hybridoma cell lines  (pTsa hybridomas) that represent this stage of Ts3 cell differen- 
tiation.  These hybridoma cells  could  be specifically activated  with  TsF2  to  release 
another antigen-specific suppressor factor (TsFa) within 6 h. The inducible feature of 
these cells permitted analysis of the signals necessary for Ts3 activation. Antigen was 
not required for activation. Only TsF2 factors derived from antiidiotypic second-order 
suppressor  cells could  activate pTs3  hybridoma cells.  There were stringent  genetic 
restrictions  on the  ability of Ys2 to activate pTsa cells.  Triggering of pTsa required 
corecognition of two determinants on the TsF2 molecular complex, i.e., the I-J and 
Igh-related idiotypic determinants. Thus, although pTs3 cells could absorb TsF2 from 
an I-J-mismatched source, these pTsa were not activated by the allogeneic TsF2. For 
activation to occur, the H-2 (I-J) and Igh complexes of the TsF2 donor had to match 
those of the strain from which the pTsa cells were derived. Mixing two distinct TsFz, 
one derived from an H-2-matched source and the other from an Igh-matched source, 
failed  to  activate  pTsa  cells.  Once  activated,  the  pTs3  cells  released  a  suppressive 
material that was indistinguishable from the TsFa factors previously characterized in 
this system. Finally, the activation of the pTs3 cells apparently does not induce the de 
novo synthesis of TsF3 since the suppressive activity could be extracted from nonacti- 
vated pTs3 cells. Thus, the inducible pTsa hybridomas represent a mature stage in the 
differentiation cycle of Ts3 cells and provide a  means for studying the nature of the 
specific signals required for Tsa activation. 
Received  for publication 25 October 1982. 
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